Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
It is the first autotaxin inhibitor to be investigated in cancer patients
Subscribe To Our Newsletter & Stay Updated
